Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk

AUTOR(ES)

Varley, Jenny

FONTE

BioMed Central

RESUMO

Germline mutations in the human checkpoint gene, hCHK2, were first identified in 1999 in cases of Li–Fraumeni syndrome. Recent studies have demonstrated that the hCHK2 1100delC mutation acts as a low-penetrance tumour suppressor gene in familial breast cancer not associated with mutations in BRCA1 or BRCA2. The present article describes the published studies on hCHK2 1100delC and addresses some of the key questions raised.

Documentos Relacionados

• Frequency of CHEK2*1100delC in New York breast cancer cases and controls
• Mutação germinativa 1100delC no gene CHEK2: estudo da frequência em famílias brasileiras com câncer de mama e cólon hereditários
• BRCA2 mutation carriers, reproductive factors and breast cancer risk
• The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia
• Mutation analysis of the CHK2 gene in breast carcinoma and other cancers